Pila Pharma
4.66 SEK +7.13%HC Andersen Capital has previously received payment from Pila Pharma for a Digital IR/Corporate Visibility agreement. This means that there may be paid material that is not updated. See disclaimer.
Be the first to follow this company
Pila Pharma operates in the pharmaceutical industry. The company conducts clinical trials in phase 2 with pharmaceuticals for type 2 diabetes. The main product is a tablet that is taken orally at an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. The business with associated research is conducted in Sweden.
Revenue
1.46M
EBIT %
-437.67 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
PILA
Daily low / high price
4.35 / 4.74
SEK
Market cap
110.88M SEK
Turnover
166.84K SEK
Volume
37K
Latest videos
Financial calendar
Interim report
2024-08-27
Annual report
2025-02-27
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Dorte X. Gram genom bolag | 21.8 % | 21.8 % |
Vimpu Intressenter AB | 16.7 % | 16.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE
PILA PHARMA PRESENTS TOMORROW AT "AKTIESPARARNA"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools